The Key that Fits: New Technique To Trace Disease-Related Agents
When PALs are used to study a specific ligand, the ligand is firstly decorated with a chemical group that can be activated when exposed to ultraviolet light, whereupon it irreversibly binds to the receptor to form a stable complex. This complex can then be thoroughly studied, e.g., by fragmentation of the receptor. Typically, formation and fragmentation of the ligand–receptor complex is traced by monitoring special tags that are incorporated into the complex. However, these tags are problematic due to high costs and size restrictions, and frequently, the tagged fragments cannot be detected among the vast excess of untagged fragments. Therefore, any potential to study the complexes is lost. Finding new ways to separate the tagged fragments from the untagged ones is one of the major challenges facing scientists today.
Grond and von Zezschwitz, together with the help of their biology colleagues Markus Huss and Helmut Wieczorek at the University of Osnabrück, have been studying V-ATPase, which is an enzyme that has been linked to osteoporosis and some cancers, to determine its mode of inhibition. To do so, they have developed a new fluorous photoaffinity label (F-PAL) that can be attached to the ligand in one step, as both the activator and the tag are contained within the same compound. The F-PAL contains a long carbon chain that is fully substituted with fluorine atoms instead of the usual hydrogen atoms. By using a special separation technique that is specific to fluorine-containing compounds, compounds with a high fluorine content can be easily “fished out” from untagged compounds. Once the tagged fragments of the ligand–receptor complexes are isolated, they can be analyzed to unravel the exact function of the drug, which could give scientists some valuable insight into how diseases such as osteoporosis and cancer can be fought.
Original publication: Stephanie Grond, et al.; "Title: New Fluorous Photoaffinity Labels (F-PAL) and Their Application in V-ATPase Inhibition Studies"; European Journal of Organic Chemistry 2010.
Most read news
Other news from the department science
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.